- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Opioid-gabapentinoid therapy for GI diseases increases risk of depression
Despite manageable gastrointestinal (GI) side effects, opioid-gabapentinoid combo therapy may be linked to a higher risk of central nervous system (CNS) depression and mortality says an article published in Frontiers in Pharmacology.
Combinations of opioid and gabapentin have become more popular, creating various security issues. There aren't many meta-analysis studies, nevertheless, that address this problem. In order to compare the risks of central nervous system depression, gastrointestinal side events, and mortality of combination therapy with those of opioid therapy and to examine the variations in outcomes according to research design and indications, Jongsung Hahn and team conducted the study.
By examining the EMBASE, MEDLINE, and CENTRAL databases, pertinent studies that were published before 30 January 2022 were chosen for this study. Using the Mantel-Haenszel method, the pooled odds ratios (OR) and 95% confidence intervals (CI) of the results were calculated. Analyses of subgroups and meta-regression were conducted in accordance with the characteristics of the study. The Risk of Bias 2 tool and the Cochrane Collaboration's Risk of Bias in Non-RCTs tool were used for the quality assessment of randomized controlled trials (RCTs) and non-randomized trials, respectively.
The key findings of the study were:
1. Mortality was observed in 10 non-RCTs, while adverse events were documented in 26 RCTs and 7 non-RCTs.
2. Dizziness, cognitive dysfunction, and respiratory depression in combination therapy considerably increased when compared to opioid therapy in non-RCTs, and a comparable trend for these side effects was also found in the RCT analysis, while the difference was not statistically significant.
3. In a subgroup analysis, combination medication for cancer pain was linked to the highest risk of sedation.
4. Constipation, vomiting, and other GI side effects were all greatly reduced by combination therapy.
5. Compared to opioid medication, the mortality risk linked with combo therapy was greater.
In conclusion, these findings imply that combination therapy, particularly in cancer patients, necessitates careful monitoring of CNS depression. Due to the lack of a risk difference in respiratory depression in the RCT-only analysis and the lack of RCT or prospective studies looking at mortality, caution should be used when interpreting the clinical findings.
Reference:
Hahn, J., Jo, Y., Yoo, S. H., Shin, J., Yu, Y. M., & Ah, Y.-M. (2022). Risk of major adverse events associated with gabapentinoid and opioid combination therapy: A systematic review and meta-analysis. In Frontiers in Pharmacology (Vol. 13). Frontiers Media SA. https://doi.org/10.3389/fphar.2022.1009950
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751